Concepts, technologies, and practices for drug delivery past the blood–brain barrier to the central nervous system

Crawford, Lindsey; Rosch, Justin G.; Putnam, David

doi:10.1016/j.jconrel.2015.12.041

Cited by 65 publications

(49 citation statements)

References 239 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 The scale of the nanomaterials allows better access to biological sites. [2][3][4] Among other applications, cancer-cell targeting would benefit greatly from highly specific and localized drug delivery. [5][6][7] Iron oxide nanoparticles (NPs) hold great promise as diagnostic and therapeutic agents in oncology.…”

Section: Introductionmentioning

confidence: 99%

Exploring cellular uptake of iron oxide nanoparticles associated with rhodium citrate in breast cancer cells

Chaves¹,

Estrela‐Lopis²,

Böttner³

et al. 2017

IJN

View full text Add to dashboard Cite

Nanocarriers have the potential to improve the therapeutic index of currently available drugs by improving their efficacy and achieving therapeutic steady-state levels over an extended period. The association of maghemite–rhodium citrate (MRC) nanoparticles (NPs) has the potential to increase specificity of the cytotoxic action. However, the interaction of these NPs with cells, their uptake mechanism, and subcellular localization need to be elucidated. This work evaluates the uptake mechanism of MRC NPs in metastatic and nonmetastatic breast cancer-cell models, comparing them to a nontumor cell line. MRC NPs uptake in breast cancer cells was more effective than in normal cells, with regard to both the amount of internalized material and the achievement of more strategic intracellular distribution. Moreover, this process occurred through a clathrin-dependent endocytosis pathway with different basal expression levels of this protein in the cell lines tested.

show abstract

Section: Introductionmentioning

confidence: 99%

Exploring cellular uptake of iron oxide nanoparticles associated with rhodium citrate in breast cancer cells

Chaves¹,

Estrela‐Lopis²,

Böttner³

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…Certain small molecule drugs may cross the BBB via lipidmediated free diffusion, providing that drug has a molecular weight of less than 400 daltons, forms not more than 8 hydrogen bonds and is relatively uncharged molecule. 11,26 Moreover, active drug transport is regulated by specic BBB transporters such as P-glycoprotein (Pgp). 29 The transporter is overexpressed on the surface of the endothelial cells in the BBB and restricts cell entry.…”

Section: Blood Brain Barriermentioning

confidence: 99%

“…[23][24][25] There are several limitations imposed by the BBB which includes molecule size, hydrophilicity, polarity, substrate specicity, and active efflux mechanisms. [26][27][28][29] These properties however, are lacking in most oxime structures. Therefore, the development of effective measures to counteract the problem of BBB penetration by oximes in order to treat OP poisoning remains a challenging issue.…”

Section: Introductionmentioning

confidence: 99%

Recent developments on oximes to improve the blood brain barrier penetration for the treatment of organophosphorus poisoning: a review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The development of medicine, pharmacology, and biotechnologies resulted in the growing interest in the design of new systems for encapsulation and delivery of drugs. Recent investigations showed that the objects of supramolecular chemistry represented by amphiphilic compounds and biocompatible polymers can provide background for the design of various types of nanocontainers (micelles, nano-and microemulsions, liposomes, polyelectrolyte capsules, and others), which can retain drugs and preserve them from adverse environmental factors along with their target delivery and long-standing effect [1][2][3][4][5][6][7][8][9]. These nanocontainers possess several advantages, among which following can be highlighted: (1) simplicity and high processability;…”

Section: Introductionmentioning

confidence: 99%

Polyelectrolyte nanocontainers: Controlled binding and release of indomethacin

Mirgorodskaya

Kushnazarova

Nikitina

et al. 2018

Journal of Molecular Liquids

View full text Add to dashboard Cite

Herein, polyelectrolyte capsules containing anti-inflammatory drug indomethacin were formed using layer-by-layer strategy, which involves alternative deposition of oppositely charged polyelectrolytes, such as poly(acrylic acid) and poly(ethyleneimine) (or chitosan) onto the drug substrate. Two variants of encapsulation have been implemented: direct deposition of polyelectrolytes onto indomethacin dispersed in water at рН 6, and preliminary formation of soft matrix by solubilization of indomethacin in micellar solutions of cationic surfactants. The inclusion of indomethacin into nanosized polyelectrolyte capsules (hydrodynamic diameter of three-and five-layer capsules is 90-180 nm) has given a new form of indomethacin with the drug content of 0.20-0.25%, which exceeds its limiting solubility in water nearly by the factor of 40. The choice of materials and procedures used for preparation of capsules, as well as the number of polyelectrolyte layers that form shell has provided the control of the drug release from capsule and resulted in the design of pharmaceutical dosage forms with long-lasting effect.

show abstract

Concepts, technologies, and practices for drug delivery past the blood–brain barrier to the central nervous system

Cited by 65 publications

References 239 publications

Exploring cellular uptake of iron oxide nanoparticles associated with rhodium citrate in breast cancer cells

Exploring cellular uptake of iron oxide nanoparticles associated with rhodium citrate in breast cancer cells

Recent developments on oximes to improve the blood brain barrier penetration for the treatment of organophosphorus poisoning: a review

Polyelectrolyte nanocontainers: Controlled binding and release of indomethacin

Contact Info

Product

Resources

About